Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation
Haifeng Wang,Wei Xue,Weigang Yan,Lei Yin,Baijun Dong,Biming He,Yongwei Yu,Wentao Shi,Zhien Zhou,Hengzhi Lin,Yi Zhou,Yanqing Wang,Zhenkai Shi,Shancheng Ren,Xu Gao,Linhui Wang,Chuanliang Xu
DOI: https://doi.org/10.1001/jamasurg.2022.2230
2022-01-01
JAMA Surgery
Abstract:<h3>Importance</h3> Focal therapy of prostate cancer must balance the oncologic outcome and functional outcome. High-frequency irreversible electroporation (H-FIRE) can destroy cancer cells while selectively preserving surrounding nerves and blood vessels, but no clinical trials have been conducted, to our knowledge. <h3>Objective</h3> To evaluate the efficacy and safety of H-FIRE in the treatment of localized prostate cancer (PCa). <h3>Design, Setting, and Participants</h3> This was a single-group, objective performance criteria, nonrandomized controlled trial. Recruitment began on May 2, 2018, and ended March 27, 2019. The follow-up duration was 6 months. This was a multicenter trial conducted at 4 tertiary teaching hospitals in China. Patients with low or intermediate risk of biochemical recurrence of localized and locally advanced PCa were eligible. Key inclusion criteria were serum prostate-specific antigen (PSA) level less than 20 ng/mL, clinical stage of T2c or less, and Gleason score of 7 or less. Data were analyzed from January 20 to February 20, 2021. <h3>Intervention</h3> H-FIRE ablation of all lesions identified with biopsy. <h3>Main Outcomes and Measures</h3> The primary end point was 6-month clinically significant PCa (csPCa), which was defined as any biopsy core with Gleason score of greater than or equal to 7, or Gleason score of 6 plus maximum cancer core length of greater than 3 mm or an increase from the original cancer burden. Secondary outcomes were calculated in patients who actually received H-FIRE treatment. <h3>Results</h3> A total of 117 patients (median [IQR] age, 67 [62-73] years) were recruited from 4 centers, and 109 patients (27 [24.8%] low risk and 82 [75.2%] intermediate risk) actually received H-FIRE. Median (IQR) PSA level was 9.0 (6.0-12.7) ng/mL. Among the 100 patients who underwent biopsy at 6 months, the 6-month csPCa rate was 6.0% (95% CI, 2.2%-12.6%;<i>P</i> < .001; 1 in the treatment zone and 5 outside the treatment zone). Superiority criteria vs the historical control of 20% was achieved. PCa was detected in 14 patients, with a Gleason score of 7 in 2 patients and 6 in the remaining 12 patients. At 6 months, median (IQR) PSA level was 1.08 (0.4-3.2) ng/mL, median (IQR) International Prostate Symptom Score was 4.5 (2.0-9.5), and median (IQR) International Index of Erectile Function 5 score was 2.0 (0.5-12.5). Superiority vs the 20% historical control was also met in the subgroup analysis that only included the 57 patients with Gleason score of 7 at baseline (3.5% 6-month csPCa; 95% CI, 0.4%-12.1%). <h3>Conclusions and Relevance</h3> The rate of 6-month csPCa with H-FIRE ablation was lower than the historical control using other energy platforms. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT03838432